Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
Date:8/6/2013

ALISO VIEJO, Calif., Aug. 6, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine-months ended June 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues of $19.8 million
  • Gross and net NUEDEXTA® sales increased to $24.3 million and $19.0 million, respectively, representing growth of 17% and 15% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $57.5 million as of June 30, 2013.
  • "Avanir continues to strengthen its position as a leading specialty biopharmaceutical company," said Keith A. Katkin, president and CEO of Avanir.  "With the NUEDEXTA franchise performing well in the U.S., a recent approval in Europe, meaningful progress with our pipeline assets and the in-licensing of an NDA-ready asset, AVP-825; we look forward to delivering on a number of exciting and potentially value-creating milestones in the coming months."

    Fiscal 2013 Third Quarter Results

  • Total net revenues for the quarter ended June 30, 2013 were $19.8 million, compared with $10.5 million for the comparable quarter in fiscal 2012, representing 87% year-over-year growth. Total net revenues consist of NUEDEXTA net revenue and royalty revenue from Abreva®.
  • Total operating expenses were $30.2 million in the third quarter of fiscal 2013, compared with $25.3 million in the comparable period in fiscal 2012.
  • Cash used in operations was $13.0 million, including a one-time milestone payment of $2 million related to AVP-786.
  • Net loss for the fiscal 2013 third quarter was $11.4 million, or $0.08 per share, compared with a net loss of $15.0 million, or $0.11 per share, f
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Avanir Pharmaceuticals to Participate in Two Conferences in August
    2. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    3. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
    4. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
    5. Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
    6. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
    7. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
    8. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
    9. AVANIR Pharmaceuticals To paticipate in two conferences in March
    10. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    11. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015 ... been reversed statewide since Pennsylvania ... the life-saving drug kits, naloxone. Heroin and ... in Pennsylvania , killing more individuals ... 2013, approximately 2,400 Pennsylvanians died from a drug overdose. ...
    (Date:8/31/2015)... DIEGO , Aug. 31, 2015 Regen ... today development of a novel means of delivering ... acid, RGBP-248, to liver tumors utilizing a clinically ... development overcomes previous hurdles with gene silencing therapeutics ... be delivered throughout the whole body.  By utilizing ...
    (Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
    Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
    ... May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today outlined its complete line ... of future products.  As a leading provider of diodes ... leverage its world-class manufacturing operations, technology expertise and packaging ...
    ... 18, 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... two upcoming investor conferences in Paris.  Dr. Fernandes will present ... a.m. CET, May 24, at the Hilton Arc de Triomphe. ... at 3:00 p.m. CET, May 24, at the Paris ...
    Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
    (Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric ... injury with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author ... has been largely untreatable - with mostly palliative treatments only - and now ...
    (Date:8/31/2015)... ... ... Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center is celebrating ... surgical and non-surgical disorders of the leg, ankle and foot. He also specializes ... , Dr. Paul Kovatis completed his orthopedic leg, ankle and foot fellowship training at ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
    (Date:8/31/2015)... Cokato, MN (PRWEB) , ... August 31, 2015 , ... ... and new product introductions: The Terrace Outdoor Sauna. After months of extensive engineering and ... attractive sauna model built to withstand the elements and is offered at a very ...
    (Date:8/31/2015)... ... 2015 , ... Wyoming Medical Center, an acute care hospital ... Documentation Improvement (CDI) and medical coding needs. Based on a proprietary Natural Language ... an enterprise-level coding solution that combines CDI, Coding, Quality and Compliance Auditing modules ...
    Breaking Medicine News(10 mins):Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4
    ... -- Researchers and clinicians from the Indiana University School ... distinction between lab and clinic as they debut the ... care model they developed and extensively tested over the ... care is on two groups -- patients with cognitive ...
    ... International Journal of Emergency Medicine, a new quarterly publication ... research developments from around the world in emergency medicine. ... be available free of charge exclusively on Springers online ... issue will be published online in March 2008. , ...
    ... CHICAGO, Feb. 19 Viola Startzman, M.D. of,Wooster, Ohio ... M.D. Award for,Excellence in Volunteerism. Presented by the American ... domestic physicians for,commitment to volunteer medical care to those ... Foundation presents the award in association with the,Pfizer Medical ...
    ... M.D.,MDiv, of Memphis, Tenn., is a recipient of the ... Medical Association (AMA) Foundation, the,award is given to domestic ... Foundation presents the award in association with the,Pfizer Medical ... Monday, March 31st, at the 2008,Excellence in Medicine Awards ...
    ... Murli Manohar, M.D., Ph.D.,FACP, of Canton, Ohio, is a ... by the American Medical Association (AMA) Foundation, the,award is ... U.S. The AMA Foundation presents the award in association ... be presented on Monday, March 31st, at the 2008,Excellence ...
    ... Choices ( http://www.nhs.uk ),the digital ,front door, to ... help people assess their drinking behaviour and improve ... Based on NHS accredited information, the drinking assessment ... seconds whether they are drinking too much, and ...
    Cached Medicine News:Health News:Merging discovery with therapy: Second generation memory care debuts 2Health News:Merging discovery with therapy: Second generation memory care debuts 3Health News:Springer to launch new journal in emergency medicine 2Health News:AMA Foundation Honors Wooster, Ohio Physician for Volunteerism 2Health News:AMA Foundation Honors Memphis, Tennessee Physician for Increasing Access to Health Care in the U.S. 2Health News:AMA Foundation Honors Canton, Ohio Physician for Increasing Access to Health Care in the U.S. 2
    The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
    The Wallac Multipette is used with 5 mL or 2.5 mL Combitips....
    The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
    ... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
    Medicine Products: